NCT07036861View on ClinicalTrials.gov

A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

April 8, 2024

Study Completion Date

January 31, 2025

Conditions

Healthy Male and Female Subjects

Interventions

DRUG

Ibuprofen 2%

Reformulated Ibuprofen 2% oral suspension (Berlin-Chemie AG)

DRUG

Ibuprofen 4%

Reformulated Ibuprofen 4% oral suspension (Berlin-Chemie AG)

DRUG

Ibuprofen 4%

Nurofen dla dzieci Forte pomarańczowy 40 mg/mL, oral suspension (Polish brand name)

Trial Locations (2)

08661

Vilnius University Hospital Santaros Klinikos, Vilnius

LT-08661

Vilnius University Hospital Santaros Klinikos, Vilnius

All Listed Sponsors

lead

Berlin-Chemie AG Menarini Group

INDUSTRY

NCT07036861 - A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension | Biotech Hunter | Biotech Hunter